Extended Data Fig. 10: Increased expression of G9a and EZH2 in non-responders treated with anti-PD-1 immunotherapy.
From: Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
Heatmap showing the supervised classification of genes bound by G9 and EZH2 in advanced urothelial carcinoma patients that responded or progressed to PD-1 treatment.
